[Federal Register Volume 61, Number 110 (Thursday, June 6, 1996)]
[Notices]
[Pages 28877-28881]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-14234]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Clinical Studies of Safety and Effectiveness of Orphan Products;
Availability of Grants; Request for Applications
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
following changes to its Orphan Products Development (OPD) grant
program for fiscal year (FY) 1997. The previous announcement of this
program, which was published in the Federal Register of August 15,
1994, is superseded by this announcement. In the future, a new
announcement will be published annually. This and future announcements
will provide the programmatic requirements and criteria, as well as the
two dates for receipt of applications, the estimated amount of funds
available, and the estimated number of awards to be made in each FY.
DATES: Application receipt dates are: October 15, 1996, and March 15,
1997. If the receipt date falls on a weekend, it will be extended to
Monday; if the date falls on a holiday, it will be extended to the
following workday.
[[Page 28878]]
ADDRESSES: Application forms are available from, and completed
applications should be submitted to: Robert L. Robins, Grants
Management Officer, Division of Contracts and Procurement Management
(HFA-520), Food and Drug Administration, Park Bldg., 5600 Fishers Lane,
rm. 3-40, Rockville, MD 20857, 301-443-6170. (Applications hand-carried
or commercially delivered should be addressed to the Park Bldg., 12420
Parklawn Dr., rm. 3-40, Rockville, MD 20857. Do not send applications
to the Division of Research Grants, National Institutes of Health
(NIH).)
FOR FURTHER INFORMATION CONTACT:
Regarding the administrative and financial management aspects of
this notice: Robert L. Robins (address above).
Regarding the programmatic aspects of this notice: Patricia R.
Robuck, Office of Orphan Products Development (HF-35), Food and Drug
Administration, 5600 Fishers Lane, rm. 8-73, Rockville, MD 20857, 301-
827-3666.
SUPPLEMENTARY INFORMATION: FDA is announcing the anticipated
availability of funds for FY 1997 for awarding grants to support
clinical trials on the safety and effectiveness of products for a rare
disease or condition (i.e., one with a prevalence, not incidence, of
fewer than 200,000 people in the United States). Contingent on
availability of FY 1997 funds, it is anticipated that $12 million will
be available, of which $8.5 million will be for noncompeting
continuation awards. This will leave $3.5 million for funding
approximately 20 new applications. Any phase clinical trial is eligible
for up to $100,000 in direct costs per annum plus applicable indirect
costs for up to 3 years. Phase 2 and 3 clinical trials are eligible for
up to $200,000 in direct costs per annum plus applicable indirect costs
for up to 3 years.
FDA will support the clinical studies covered by this notice under
section 301 of the Public Health Service Act (the PHS act) (42 U.S.C.
241). FDA's research program is described in the Catalog of Federal
Domestic Assistance, No. 93.103.
The Public Health Service (PHS) strongly encourages all grant
recipients to provide a smoke-free work place and to discourage the use
of all tobacco products. This is consistent with the PHS mission to
protect and advance the physical and mental health of the American
people.
PHS urges applicants to submit work plans that address specific
objectives of ``Healthy People 2000.'' Potential applicants may obtain
a copy of ``Healthy People 2000'' (Full Report, stock no. 017-001-
00474-0) or ``Healthy People 2000'' (Summary Report, stock no. 017-001-
00473-1) through the Superintendent of Documents, Government Printing
Office, Washington, DC 20402-9325, 202-783-3238.
PHS policy is that applicants for PHS clinical research grants are
required to include minorities and women in study populations so that
research findings can be of benefit to all persons at risk of the
disease, disorder, or condition under study; special emphasis must be
placed on the need for inclusion of minorities and women in studies of
diseases, disorders, and conditions which disproportionately affect
them. This policy is intended to apply to males and females of all
ages. If women or minorities are excluded or inadequately represented
in clinical research, particularly in proposed population-based
studies, a clear compelling rationale must be provided.
I. Program Research Goals
OPD was established to identify and facilitate the availability of
orphan products. In the OPD grant program, orphan products are defined
as drugs, biologics, medical devices, and foods for medical purposes,
which are indicated for a rare disease or condition (i.e., one with a
prevalence, not incidence, of fewer than 200,000 people in the United
States). Diagnostic tests and vaccines will qualify only if the U.S.
population of intended use is lower than 200,000.
One way to make orphan products available is to support clinical
research to determine whether the products are safe and effective. All
funded studies are subject to the requirements of the Federal Food,
Drug, and Cosmetic Act (the act) and regulations issued thereunder. The
grants are funded under the legislative authority of section 301 of the
PHS Act (42 U.S.C. 241).
The goal of FDA's OPD grant program is to encourage clinical
development of products for use in rare diseases or conditions where no
current therapy exists or where current therapy would be improved. FDA
provides grants to conduct clinical studies intended to provide data
acceptable to the agency which will either result in or substantially
contribute to approval of these products. Applicants should keep this
goal in mind and must include an explanation in the ``Background and
Significance'' section of the application of how their proposed study
will either facilitate product approval or provide essential data
needed for product development. Information regarding meetings and/or
discussions with FDA reviewing division staff about the product to be
studied should also be provided as an appendix to the application. This
information is extremely important for the review process.
Except for medical foods that do not require premarket approval,
FDA will only consider awarding grants to support clinical studies for
determining whether the products are safe and effective for premarket
approval under the act (21 U.S.C. 301 et seq.) or under section 351 of
the PHS Act (42 U.S.C. 262). All studies of new drug and biological
products must be conducted under FDA's investigational new drug (IND)
procedures and studies of medical devices must be conducted under the
investigational device exemption (IDE) procedures. Studies of approved
products to evaluate new orphan indications are also acceptable;
however, these are also required to be conducted under an IND or IDE to
support a change in official labeling. (See section V.B. of this
document (Program Review Criteria) for critical requirements concerning
IND/IDE status of products to be studied under these grants.)
Studies submitted for the larger grants ($200,000) must be
continuing in phase 2 or phase 3 of investigation. Phase 2 trials
include controlled clinical studies conducted to evaluate the
effectiveness of the product for a particular indication in patients
with the disease or condition and to determine the common or short-term
side effects and risks associated with it. Phase 3 trials gather
additional information about effectiveness and safety that is necessary
to evaluate the overall risk-benefit relationship of the product and to
provide an adequate basis for physician labeling. Studies submitted for
the smaller grants ($100,000) may be phase 1, 2, or 3 trials.
Applications must propose a clinical trial of one therapy for one
indication. The applicant must provide supporting evidence that a
sufficient quantity of the product to be investigated is available to
the applicant in the form needed for the clinical trial. The applicant
must also provide supporting evidence that the patient population has
been surveyed and that there is reasonable assurance that the necessary
number of eligible patients is available for the study.
Funds may be requested in the budget for travel to FDA to meet with
reviewing division staff about product development progress.
[[Page 28879]]
II. Human Subject Protection and Informed Consent
A. Research Involving Human Subjects
Applicants should carefully review the section on human subjects in
the application kit. ``Section C. Specific Instructions--Forms, Item 4,
Human Subjects,'' on pages 7 and 8 of the application kit should be
carefully reviewed for the certification of Institutional Review Board
(IRB) approval requirements. Documentation of IRB approval for every
participating center is required to be on file with the Grants
Management Officer, FDA. The goal should be to include enough
information on the protection of human subjects in a sufficiently clear
fashion so reviewers will have adequate material to make a complete
review.
B. Informed Consent
Consent and/or assent forms, and any additional information to be
given to a subject, should accompany the grant application. Information
that is given to the subject or the subject's representative must be in
language that the subject or his or her representative can understand.
No informed consent, whether oral or written, may include any language
through which the subject or the subject's representative is made to
waive any of the subject's legal rights, or by which the subject or
representative releases or appears to release the investigator, the
sponsor, or the institution or its agent from liability.
If a study involves both adults and children, separate consent
forms should be provided for the adults and the parents or guardians of
the children.
C. Elements of Informed Consent
The elements of informed consent are stated in the regulations at
45 CFR 46.116 and 21 CFR 50.25 as follows:
1. Basic Elements of Informed Consent
In seeking informed consent, the following information shall be
provided to each subject.
(a) A statement that the study involves research, an explanation of
the purposes of the research and the expected duration of the subject's
participation, a description of the procedures to be followed, and
identification of any procedures which are experimental.
(b) A description of any reasonably foreseeable risks or
discomforts to the subject.
(c) A description of any benefits to the subject or to others which
may reasonably be expected from the research.
(d) A disclosure of appropriate alternative procedures or courses
of treatment, if any, that might be advantageous to the subject.
(e) A statement that describes the extent, if any, to which
confidentiality of records identifying the subject will be maintained,
and that notes the possibility that FDA may inspect the records.
(f) For research involving more than minimal risk, an explanation
as to whether any compensation and any medical treatments are available
if injury occurs and, if so, what they consist of or where further
information may be obtained.
(g) An explanation of whom to contact for answers to pertinent
questions about the research and research subject's rights, and whom to
contact in the event of research-related injury to the subject.
(h) A statement that participation is voluntary, that refusal to
participate will involve no penalty or loss of benefits to which the
subject is otherwise entitled, and that the subject may discontinue
participation at any time without penalty or loss of benefits to which
the subject is otherwise entitled.
2. Additional Elements of Informed Consent
When appropriate, one or more of the following elements of
information shall also be provided to each subject.
(a) A statement that the particular treatment or procedure may
involve risks to the subject (or the embryo or fetus, if the subject is
or may become pregnant), which are currently unforeseeable.
(b) Anticipated circumstances under which the subject's
participation may be terminated by the investigator without regard to
the subject's consent.
(c) Any costs to the subject that may result from participation in
the research.
(d) The consequences of a subject's decision to withdraw from the
research and procedures for orderly termination of participation by the
subject.
(e) A statement that significant new findings developed during the
course of the research which may relate to the subject's willingness to
continue participation will be provided to the subject.
(f) The approximate number of subjects involved in the study.
The informed consent requirements are not intended to preempt any
applicable Federal, State, or local laws which require additional
information to be disclosed for informed consent to be legally
effective.
Nothing in the notice is intended to limit the authority of a
physician to provide emergency medical care to the extent that a
physician is permitted to do so under applicable Federal, State, or
local law.-
III. Reporting Requirements
An annual Financial Status Report (SF-269) is required. The
original and two copies of this report must be submitted to FDA's
Grants Management Officer within 90 days of the budget expiration date
of the grant. Failure to file the Financial Status Report (SF-269) in a
timely fashion will be grounds for suspension or termination of the
grant.
For continuing grants, an annual program progress report is also
required. The noncompeting continuation application (PHS 2590) will be
considered the annual program progress report.
Additionally, all continuing grants must comply with all regulatory
requirements necessary to maintain active status of their IND/IDE. This
includes, but is not limited to, submission of an annual report to the
appropriate regulatory review division within FDA. Failure to meet
regulatory requirements will be grounds for suspension or termination
of the grant.-
Program monitoring of grantees will be conducted on an ongoing
basis and written reports will be prepared by the project officer. The
monitoring may be in the form of telephone conversations between the
project officer/grants management specialist and the principal
investigator. Periodic site visits with appropriate officials of the
grantee organization may also be conducted. The results of these
reports will be recorded in the official grant file and may be
available to the grantee upon request consistent with FDA disclosure
regulations.
A final program progress report, Financial Status Report (SF-269),
and Invention Statement must be submitted within 90 days after the
expiration of the project period as noted on the Notice of Grant Award.
IV. Mechanism of Support
A. Award Instrument
Support will be in the form of a grant. All awards will be subject
to all policies and requirements that govern the research grant
programs of PHS, including the provisions of 42 CFR part 52 and 45 CFR
parts 74 and 92. The regulations issued under Executive Order 12372 do
not apply to this program.
All grant awards are subject to applicable requirements for
clinical investigations imposed by sections 505, 507, 512, and 515 of
the act (21 U.S.C. 355, 357, 360b, and 360e), section 351
[[Page 28880]]
of the PHS act (42 U.S.C. 262), and regulations promulgated under any
of these sections.
B. Eligibility
These grants are available to any public or private nonprofit
entity (including State and local units of government) and any for-
profit entity. For-profit entities must commit to excluding fees or
profit in their request for support.
C. Length of Support
The length of the study will depend upon the nature of the study.
For those studies with an expected duration of more than 1 year, a
second or third year of noncompetitive continuation of support will
depend on: (1) Performance during the preceding year; (2) the
availability of Federal funds; and (3) compliance with regulatory
requirements of the IND/IDE.
D. Funding Plan
The number of studies funded will depend on the quality of the
applications received and the availability of Federal funds to support
the projects. Before an award will be made, OPD will verify the active
status of the IND/IDE for the proposed study. If the IND/IDE for the
proposed study is not active, no award will be made. Further,
documentation of IRB approvals for all performance sites must be on
file with the Grants Management Officer, FDA (address above), before an
award can be made.
V. Review Procedure and Criteria
A. Review Method
All applications submitted in response to this request for
applications (RFA) will first be reviewed by grants management and
program staff for responsiveness to this RFA. If applications are found
to be nonresponsive, they will be returned to the applicant without
further consideration.
Responsive applications will be reviewed and evaluated for
scientific and technical merit by an ad hoc panel of experts in the
subject field of the specific application. Responsive applications will
also be subject to a second level of review by a National Advisory
Council for concurrence with the recommendations made by the first-
level reviewers, and funding decisions will be made by the Commissioner
of Food and Drugs.
B. Program Review Criteria
Applications will be evaluated by program and grants management
staff for responsiveness. Applications considered nonresponsive will be
returned to the applicant, unreviewed. Applicants are strongly
encouraged to contact FDA to resolve any questions regarding criteria
prior to the submission of their application. All questions of a
technical or scientific nature must be directed to the OPD program
staff and all questions of an administrative or financial nature must
be directed to the grants management staff. (See ``For Further
Information Contact'' section of this document.) Responsiveness will be
based on the following criteria:
1. The application must propose a clinical trial intended to
provide safety and/or efficacy data of one therapy for one orphan
indication. Additionally, there must be an explanation in the
``Background and Significance'' section of how the proposed study will
either facilitate product approval or provide essential data needed for
product development.
2. The prevalence, not incidence, of the population to be served by
the product must be fewer than 200,000 individuals in the United
States. The applicant should include, in the ``Background and
Significance'' section, a detailed explanation supplemented by
authoritative references in support of the prevalence figure. If the
product has been designated by FDA as an orphan product for the
proposed indication, a statement of that fact will suffice. Diagnostic
tests and vaccines will qualify only if the population of intended use
is fewer than 200,000 individuals in the United States.
3. The number assigned to the IND/IDE for the proposed study should
appear on the face page of the application with the title of the
project. Only medical foods that do not require premarket approval are
exempt from this requirement. The IND/IDE must be in active status and
in compliance with all regulatory requirements of FDA at the time of
submission of the application. In order to meet this requirement, the
original IND/IDE application, pertinent amendments, and the protocol
for the proposed study must have been submitted to FDA a minimum of 30
days prior to the due date of the grant application. Studies of already
approved products, evaluating new orphan indications, must also have an
active IND. Exempt IND's must have their status changed to active to be
eligible for this program. If the sponsor of the IND/IDE is other than
the principal investigator listed on the application, a letter from the
sponsor verifying access to the IND/IDE is required, and both the
identity of the application's principal investigator and the study
protocol must have been submitted to the IND/IDE.
4. The requested budget should be within the limits (either
$100,000 in direct costs for up to 3 years for any phase study, or
$200,000 in direct costs for up to 3 years for phase 2 or 3 studies) as
stated in this RFA.
5. Consent and/or assent forms, and any additional information to
be given to a subject, should be included in the grant application.
6. All applicants should follow guidelines specified in the PHS 398
Grant Application kit.
C. Scientific/Technical Review Criteria
The ad hoc expert panel will provide the first level of review. The
application will be judged on the following scientific and technical
merit criteria:
1. The soundness of the rationale for the proposed study;
2. The quality and appropriateness of the study design to include
the rationale for the statistical procedures;
3. The statistical justification for the number of patients chosen
for the trial, based on the proposed outcome measures and the
appropriateness of the statistical procedures to be used in analysis of
the results;
4. The adequacy of the evidence that the proposed number of
eligible subjects can be recruited in the requested timeframe;
5. The qualifications of the investigator and support staff, and
the resources available to them;
6. The evidence that a sufficient quantity of the product is
available to the applicant in the form needed for the investigation. A
current letter from the supplier as an appendix will be acceptable;
7. The adequacy of the justification for the request for financial
support;
8. The adequacy of plans for complying with regulations for
protection of human subjects; and
9. The ability of the applicant to complete the proposed study
within its budget and within time limitations stated in this RFA.
The priority score will be based on the scientific/technical review
criteria in section V.C. of this document. In addition, the reviewers
may advise the program staff concerning the appropriateness of the
proposal to the goals of the OPD Grant Program described in section I.
(Program Research Goals) of this document.
D. Award Criteria
Resources for this program are limited. Therefore, should two or
more applications be received and approved by FDA which propose
duplicative or
[[Page 28881]]
very similar studies, FDA will support only the study with the best
score.
VI. Submission Requirements
The original and five copies of the completed Grant Application
Form PHS 398 (Rev. 5/95) or the original and two copies of the PHS 5161
(Rev. 7/92) for State and local governments, with copies of the
appendices for each of the copies, should be delivered to Robert L.
Robins (address above). State and local governments may choose to use
the PHS 398 application form in place of the PHS 5161. Application
receipt dates are October 15, 1996, and March 15, 1997. If the receipt
date falls on a weekend, it will be extended to Monday; if the date
falls on a holiday, it will be extended to the following workday. No
supplemental or addendum material will be accepted after the receipt
date. Evidence of final IRB approval will be accepted for the file
after the receipt date.
The outside of the mailing package and item 2 of the application
face page should be labeled, ``Response to RFA FDA OP-97-1''-
If an application for the same study was submitted in response to
the previous RFA, a submission in response to this RFA will be
considered a request to withdraw the previous application. Applications
originally submitted for the October closing date will also be
administratively withdrawn, if resubmitted the following March.
Resubmissions are treated as new applications; therefore, the applicant
may wish to include previous summary statements from past reviews.
VII. Method of Application
A. Submission Instructions-
Applications will be accepted during normal working hours, 8 a.m.
to 4:30 p.m., Monday through Friday, on or before the established
receipt dates.
Applications will be considered received on time if sent or mailed
on or before the receipt dates as evidenced by a legible U.S. Postal
Service dated postmark or a legible date receipt from a commercial
carrier, unless they arrive too late for orderly processing. Private
metered postmarks shall not be acceptable as proof of timely mailing.
Applications not received on time will not be considered for review and
will be returned to the applicant. (Applicants should note that the
U.S. Postal Service does not uniformly provide dated postmarks. Before
relying on this method, applicants should check with their local post
office.)
B. Format for Application-
Submission of the application must be on Grant Application Form PHS
398 (Rev. 5/95). All ``General Instructions'' and ``Specific
Instructions'' in the application kit should be followed with the
exception of the receipt dates and the mailing label address. Do not
send applications to the Division of Research Grants, NIH. Applications
from State and local governments may be submitted on Form PHS 5161
(Rev. 7/92) or Form PHS 398 (Rev. 5/95).-
The face page of the application should reflect RFA-FDA-OP-97-1.
The title of the proposed study should include the name of the product
and the disease/disorder to be studied along with the IND/IDE number. -
Data included in the application, if restricted with the legend
specified below, may be entitled to confidential treatment as trade
secret or confidential commercial information within the meaning of the
Freedom of Information Act (5 U.S.C. 552(b)(4)) and FDA's implementing
regulations (21 CFR 20.61).-
Information collection requirements requested on Form PHS 398 and
the instructions have been submitted by the PHS to the Office of
Management and Budget (OMB) and were approved and assigned OMB control
number 0925-0001.
C. Legend-
Unless disclosure is required by the Freedom of Information Act as
amended (5 U.S.C. 552) as determined by the freedom of information
officials of the Department of Health and Human Services or by a court,
data contained in the portions of this application which have been
specifically identified by page number, paragraph, etc., by the
applicant as containing restricted information shall not be used or
disclosed except for evaluation purposes.
Dated: May 29, 1996.
William K. Hubbard,
Associate Commissioner for Policy Coordination.
[FR Doc. 96-14234 Filed 6-5-96; 8:45 am]
BILLING CODE 4160-01-F